Journal
CURRENT TOPICS IN MEDICINAL CHEMISTRY
Volume 12, Issue 14, Pages 1479-1499Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/156802612802652420
Keywords
Histone deacetylase; HDAC inhibitor; isoform; isozyme; cancer; inflammation; metabolic
Categories
Funding
- Australian National Health and Medical Research Council [APP569735]
- Senior Principal Research Fellowship [APP1027369]
- Australian Research Council for a Future Fellowship [FT100100657]
- Federation Fellowship [FF0668733]
Ask authors/readers for more resources
Histone deacetylase (HDAC) enzymes have emerged as promising targets for the treatment of a wide range of human diseases, including cancers, inflammatory and metabolic disorders, immunological, cardiovascular, and infectious diseases. At present, such applications are limited by the lack of selective inhibitors available for each of the eighteen HDAC enzymes, with most currently available HDAC inhibitors having broad-spectrum activity against multiple HDAC enzymes. Such broad-spectrum activity maybe useful in treating some diseases like cancers, but can be detrimental due to cytotoxic side effects that accompany prolonged treatment of chronic diseased states. Here we summarize progress towards the design and discovery of HDAC inhibitors that are selective for some of the eleven zinc-containing classical HDAC enzymes, and identify opportunities to use such isozyme-selective inhibitors as chemical probes for interrogating the biological roles of individual HDAC enzymes in diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available